Patents matching “ONC”

US 8716473

Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase

SENTINEL ONCOLOGY LIMITED · Granted May 6, 2014 · Expires May 1, 2034

US 8709478

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Apr 29, 2014 · Expires Apr 24, 2034

US 8709443

Reovirus for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Apr 29, 2014 · Expires Apr 24, 2034

US 8691241

Reoviruses having modified sequences

ONCOLYTICS BIOTECH INC. · Granted Apr 8, 2014 · Expires Apr 3, 2034

US 8685734

Viral purification methods

ONCOLYTICS BIOTECH INC. · Granted Apr 1, 2014 · Expires Mar 27, 2034

US 8680066

Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject

The United States of America as represented by the Development of Veterans Affairs · Granted Mar 25, 2014 · Expires Mar 20, 2034

US 8658158

Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

ONCOLYTICS BIOTECH INC. · Granted Feb 25, 2014 · Expires Feb 20, 2034

WO 2013169458

COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES DE TRAITEMENT, DE CONTRÔLE, D'AMÉLIORATION, OU D'INVERSION DES TROUBLES DE LA KÉRATOCONJONCTIVITE SÈCHE

BAUSCH & LOMB [US] · Granted Nov 14, 2013 · Expires Nov 9, 2033

US 8529916

High concentration baclofen preparations

The Board of Regents of the University of Texas System · Granted Sep 10, 2013 · Expires Sep 5, 2033

US 8512712

Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

ONCOLYTICS BIOTECH INC. · Granted Aug 20, 2013 · Expires Aug 15, 2033

US 8491886

Viruses for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Jul 23, 2013 · Expires Jul 18, 2033

US 8491884

Virus clearance of neoplastic cells from mixed cellular compositions

ONCOLYTICS BIOTECH INC. · Granted Jul 23, 2013 · Expires Jul 18, 2033

US 8491893

Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications

Quantum Immunologics, Inc. · Granted Jul 23, 2013 · Expires Jul 18, 2033

US 8474529

Control of concentric tubing direction

Regency Technologies LLC · Granted Jul 2, 2013 · Expires Jun 27, 2033

US 8470364

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Jun 25, 2013 · Expires Jun 20, 2033

US 8470312

Abrogating proinflammatory cytokine production during oncolytic reovirus therapy

ONCOLYTICS BIOTECH INC. · Granted Jun 25, 2013 · Expires Jun 20, 2033

US 8461339

Pharmaceutical compounds

SENTINEL ONCOLOGY LIMITED · Granted Jun 11, 2013 · Expires Jun 6, 2033

US 8449911

Drug composition having active ingredient adhered at high concentration to spherical core

Takeda Pharmaceutical Company Limited · Granted May 28, 2013 · Expires May 23, 2033

US 8445541

Methods for concomitant administration of colchicine and a second active agent

Takeda Pharmaceuticals U.S.A., Inc. · Granted May 21, 2013 · Expires May 16, 2033

US 8440721

Methods for concomitant administration of colchicine and a second active agent

Takeda Pharmaceuticals U.S.A., Inc. · Granted May 14, 2013 · Expires May 9, 2033

US 8440722

Methods for concomitant administration of colchicine and a second active agent

Takeda Pharmaceuticals U.S.A., Inc. · Granted May 14, 2013 · Expires May 9, 2033

US 8394405

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

US 8394406

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

US 8372848

Melanin-concentrating hormone receptor antagonists and methods of use

The Regents of the University of California · Granted Feb 12, 2013 · Expires Feb 7, 2033